Amit Sachdev
CIK 1406338 · EVP Chief Patient & Ext Af Off · last filed 2026-07-23
Amit Sachdev is an EVP Chief Patient & Ext Af Off who has filed 156 SEC Form 4 insider transactions across 2 companies since 2007. The most recent filing, for VRTX, was dated Jul 23, 2026. Across all open-market trades the lifetime net is −$171.4M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $37.3M across reported positions. 153 SEC filings were submitted jointly with VERTEX PHARMACEUTICALS INC / MA.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
VRTX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
50 NORTHERN AVENUE
BOSTON, MA 02210
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| VRTX | EVP Chief Patient & Ext Af Off | 73,149 | $510.08 | $37.31M | -$171.36M | 142 | 2026-07-23 |
| Eiger BioPharmaceuticals, Inc. (EIGR) Delisted | Director | 533 | $1.73 | $919 | $0 | 5 | 2023-03-03 |
Recent Filings
156 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-23 | VRTX | Grant (A) | +8,251 | $0 | EDGAR |
| 2026-02-26 | VRTX | Mixed | −3,364 | -$1.63M | EDGAR |
| 2026-02-25 | VRTX | Notice (144) | −1,846 | -$897.8K | EDGAR |
| 2026-02-23 | VRTX | Mixed | −10,108 | -$19.13M | EDGAR |
| 2026-02-19 | VRTX | Notice (144) | −58,613 | -$27.48M | EDGAR |
| 2026-02-19 | VRTX | Mixed | +3,649 | -$1.04M | EDGAR |
| 2026-02-18 | VRTX | Tax (F) | −3,548 | -$1.73M | EDGAR |
| 2026-02-12 | VRTX | Tax (F) | −2,057 | -$963.5K | EDGAR |
| 2026-01-26 | VRTX | Grant (A) | +11,749 | $0 | EDGAR |
| 2025-02-28 | VRTX | Tax (F) | −3,703 | -$1.78M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.